Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
Androgel save search
Personal Safety Tracking Devices Market size is set to grow by USD 650.34 million from 2023-2027, AllsWell LLC, Amber Alert GPS Inc. and Angel Sense Ltd., and more to emerge as Some of the Key Vendors, Technavio
Published: 2024-04-17 (Crawled : 23:00) - prnewswire.com
GTXO | $0.06
|
Manufacturing
| Email alert
Add to watchlist
personal million alert set key market
Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate Cancer
Published: 2024-04-11 (Crawled : 11:00) - globenewswire.com
NVS | News | $97.28 2.27% 0.31% 3.7M
|
Health Technology
|
| O: 0.32%
H: 0.04%
C: -0.56%
ARVN | $33.96 -2.69% -2.77% 530K
|
Health Technology
|
| O: 8.28%
H: 0.56%
C: -4.75%
arv-766 protac license cancer treatment global protein for commercialization agreement
Washington Trust Appoints Debra M. Paul and Angel Taveras To Board of Directors
Published: 2024-02-12 (Crawled : 22:00) - prnewswire.com
WASH | $26.43 2.64% 2.57% 89K
|
Finance
|
| O: -3.01%
H: 0.0%
C: -4.53%
trust
Veru Reports Clinical Data from the Discontinued ARTEST Study of Enobosarm, Novel Selective Androgen Receptor Targeting Agonist, in AR+ ER+ HER2- Metastatic Breast Cancer
Published: 2023-09-11 (Crawled : 11:00) - globenewswire.com
LLY | News | $745.69 1.96% -0.16% 2M
|
Health Technology
|
| O: 2.42%
H: 0.0%
C: 0.0%
VERU | $1.27 0.0% 2.6M
|
Health Technology
|
| O: 1.45%
H: 0.95%
C: 0.0%
breast cancer her2- study
Oncternal Therapeutics Receives FDA Study May Proceed Letter for ONCT-534, its Novel Dual-action Androgen Receptor Inhibitor, for the Treatment of Patients with Advanced Prostate Cancer
Published: 2023-08-03 (Crawled : 20:00) - globenewswire.com
ONCT | $8.98 5.03% 4.79% 960
|
Health Technology
|
| O: 2.29%
H: 0.26%
C: -8.74%
onct-534 fda cancer treatment therapeutics study
ERLEADA® (apalutamide), First-and-Only Next-Generation Androgen Receptor Inhibitor with Once-Daily, Single-Tablet Option Now Available in the U.S.
Published: 2023-04-03 (Crawled : 16:00) - biospace.com/
JNJ | News | $149.56 0.3% 0.0% 9.1M
|
Health Technology
|
| O: -0.03%
H: 1.33%
C: 1.23%
erleada
PG&E and Angel Island Ferry Partner to Launch California's First Zero-Emission, Electric Short-Run Ferry
Published: 2023-02-13 (Crawled : 20:00) - prnewswire.com
PCG | News | $16.96 0.06% 0.58% 9.6M
|
Utilities
|
| O: -0.38%
H: 1.41%
C: -0.13%
Merck Announces KEYNOTE-991 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Enzalutamide and Androgen Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer to Stop for Futility
Published: 2023-01-25 (Crawled : 12:00) - biospace.com/
MRK | $126.88 -0.05% -0.13% 7.5M
|
Health Technology
|
| O: 0.18%
H: 1.12%
C: -0.11%
ynote-991 keytruda trial plus therapy cancer prostate cancer
ESSA Pharma Presents Preclinical Data for its First Generation Androgen Receptor N-Terminal Domain Degrader at the 34th EORTC-NCI-AACR Symposium
Published: 2022-10-26 (Crawled : 22:00) - biospace.com/
EPIX | $6.475 1.17% 1.16% 130K
|
Health Technology
|
| O: 19.19%
H: 148.78%
C: 135.12%
pharma preclinical symposium
Clarus Therapeutics Announces Notice of Allowance for Patent Claims Covering CLAR-121 (Testosterone + Anastrozole) for Treatment of Androgen-Mediated Autoimmune Inflammatory Mastitis
Published: 2022-05-10 (Crawled : 13:20) - globenewswire.com
CRXT | $0.0475
|
|
| O: 4.55%
H: 4.98%
C: -6.38%
clar-121 treatment patent therapeutics
Clarus Therapeutics to Present New Data for JATENZO® (testosterone undecanoate) at the Androgen Society 4th Annual Meeting
Published: 2022-04-19 (Crawled : 14:00) - biospace.com/
CRXT | $0.0475
|
|
| O: 7.56%
H: 17.19%
C: 13.28%
jatenzo therapeutics
ESSA Pharma Announces the Presentation of Preclinical Data for its First Generation of Androgen Receptor N-Terminal Domain Degraders
Published: 2022-04-08 (Crawled : 19:00) - biospace.com/
EPIX | $6.475 1.17% 1.16% 130K
|
Health Technology
|
| O: 1.77%
H: 2.67%
C: -1.34%
pharma preclinical presentation pre-clinical
ESSA Pharma to Present Preclinical Data for its First Generation of Androgen Receptor N-Terminal Domain Degraders at the 2022 American Association for Cancer Research (AACR) Annual Meeting
Published: 2022-03-08 (Crawled : 22:00) - prnewswire.com
EPIX | $6.475 1.17% 1.16% 130K
|
Health Technology
|
| O: 0.28%
H: 0.0%
C: 0.0%
america research preclinical cancer pre-clinical
Veru Enrolls First Patient in Phase 3 VERACITY Clinical Trial of Sabizabulin (VERU-111) in Metastatic Castration Resistant and Androgen Receptor Targeting Agent Resistant Prostate Cancer
Published: 2021-06-25 (Crawled : 13:00) - globenewswire.com
VERU | $1.27 0.0% 2.6M
|
Health Technology
|
| O: 1.46%
H: 0.96%
C: -1.8%
prostate cancer cancer phase 3 trial enroll sabizabulin
Veru Announces Positive Phase 2 Clinical Data: Efficacy of Enobosarm Therapy Correlates with Androgen Receptor Levels in AR+ER+HER2- Metastatic Breast Cancer Presented at the 2021 ASCO Annual Meeting
Published: 2021-06-07 (Crawled : 13:00) - globenewswire.com
VERU | $1.27 0.0% 2.6M
|
Health Technology
|
| O: 0.92%
H: 5.56%
C: 1.82%
phase 2 positive therapy cancer breast cancer her2+ her2- her2 metastatic breast cancer
Veru Announces Presentation of Phase 2 Study of Enobosarm -- a Selective Androgen Receptor Targeting Agent in Metastatic AR+ER+HER2- Breast Cancer at 2021 ESMO Breast Cancer Congress
Published: 2021-04-21 (Crawled : 13:00) - globenewswire.com
VERU | $1.27 0.0% 2.6M
|
Health Technology
|
| O: -0.79%
H: 5.11%
C: 4.88%
presentation phase 2 cancer breast cancer her2+ her2- her2
Cardiff Oncology in Collaboration with MIT Presents Gene Signature Analyses Data Identifying Androgen-Independent Mechanism for Onvansertib-Abiraterone Synergy in mCRPC
Published: 2021-04-10 (Crawled : 16:20) - prnewswire.com
CRDF | $4.17 -4.36% -4.56% 700K
|
Health Services
| Email alert
Add to watchlist
collaboration onvansertib
Lilly and Rigel Enter Strategic Collaboration to Develop RIPK1 Inhibitors for the Potential Treatment of Immunological and Neurodegenerative Diseases
Published: 2021-02-18 (Crawled : 12:11) - prnewswire.com
LLY | News | $745.69 1.96% -0.16% 2M
|
Health Technology
|
| O: -0.56%
H: 0.06%
C: -2.04%
RIGL | $1.135 0.44% 0.44% 520K
|
Health Technology
|
| O: 17.44%
H: 3.38%
C: -10.53%
disease treatment neurodegenerative collaboration potential
Histogen Announces Week 26 HST-001 Study Results for the Treatment of Androgenic Alopecia in Men
Published: 2021-02-16 (Crawled : 13:03) - globenewswire.com
HSTO 4 d | $0.5 67.46% 530
|
Health Technology
|
| O: 1.16%
H: 2.3%
C: -5.17%
treatment results
Veru Reports Positive Phase 2 Clinical Trial Results for Enobosarm, Selective Androgen Receptor Targeting Agent, for Endocrine Resistant Metastatic Breast Cancer
Published: 2020-12-14 (Crawled : 13:01) - globenewswire.com
VERU | $1.27 0.0% 2.6M
|
Health Technology
|
| O: 55.31%
H: 9.73%
C: -1.77%
results breast cancer cancer positive endocrine trial trial results phase 2 metastatic breast cancer
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News 4 | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.